Sold by: Global Market Insights Inc.
Deployed on AWS
The hemophilia treatment market value is expected to witness 5% CAGR growth from 2023 to 2032 driven by a significant rise in R&D investments to support the development of novel drugs coupled with the increasing rollouts of favorable government initiatives.
Overview
The latest report published by Global Market Insights Inc. suggests that the **hemophilia treatment market size **may exceed USD 16 billion by 2028. Rising health awareness among people of all income groups, accompanied by the increasing healthcare expenditure and the penetration of several health policies, may transform the market dynamics.
The rapid growth in the number of patients with hemophilia has encouraged government and non-government authorities globally to take necessary initiatives and promote awareness about the disease symptoms, diagnosis, and treatment.
Healthcare authorities have been collaborating with pharmaceutical giants to look for effective treatment and ensure quality care for those living with hemophilia. Such efforts are likely to strengthen the industry forecast.
Some of the fields available in report -
| Required Fields | Format |
|---|---|
| Market Size in 2021 | USD 11 Billion |
| Value Projection by 2028 | USD 16 Billion |
| **Compound Annual Growth Rate (CAGR) ** | 5% |
| ** Hemophilia B segment CAGR** | 3.5% |
| ** Pediatric segment CAGR** | 5.1% |
| ** Injectable segment CAGR** | 4.9% |
| U.S Market in 2028 | 6.2 Billion |
| No. Of Tables | 791 |
| Figures & Charts | 24 |
| No. Of Report Pages | 350 |
| Countries covered in the report | U.S., Canada, UK, France, Italy, Germany, Spain, China, India, Japan, South Korea, Australia, Mexico, Brazil, Argentina, UAE, Saudi Arabia, South Africa. |
| Segments covered | Disease, Product, Patient, Treatment, Therapy, Drug class, Route of administration, End-use. |
Companies covered in the report | Bayer Healthcare,Biogen, Biotest AG,CSL Behring, Ferring B.V., Genentech, Kedrion, Novo Nordisk, Octapharma, Pfizer, Sanofi SA, Swedish Orphan Biovitrum AB.
** Surging number of patients with hemophilia**
As per the US Center for Disease Control and Prevention, every 1 in 5,000 male births in the United States is affected by hemophilia A, with over 400 babies being born with the disease each year. Over 1,36,000 people in India have been diagnosed with hemophilia constituting 1 in every 10,000 male births. Out of these, around 19,690 are diagnosed with hemophilia A.
While these statistics are alarming enough to look for opportunities and possible treatment for the affected population, estimations by the WFH are further overwhelming.
The World Federation of Hemophilia, based on 2021 population estimates, claimed that more than 75% of the total 815,000 people living with hemophilia remain undiagnosed and lose a chance to lead a more normal life.
**Request for a free sample of this research report @ https://www.gminsights.com/request-sample/detail/2772**
** Novel drug launches**
In the present scenario, the hemophilia ecosystem has been dealing with a number of challenges, including disease awareness and quality factor availability among several stakeholders, and accessibility to therapy and treatment centers.
However, several organizations are undertaking R&D projects and working towards providing effective patient care and treatment.
For instance, in June 2022, the EMA suggested endowing a conditional marketing authorization for Roctavian (valoctocogene roxaparvovec) in the EU (European Union) for treating adults with acute hemophilia A having no antibodies to adeno-associated virus serotype 5 (AAV5) and lacking factor VIII inhibitors.
Such drug deliveries and treatments will significantly boost the adoption of hemophilia inhibitors, which will stimulate the hemophilia market outlook.
In addition to these factors, factor replacement therapy which is prompt treatment of swollen joints and can be performed at home may fuel the industry landscape due to fewer hospital visits.
As awareness about early disease diagnosis and treatment grows, more and more people will opt for quicker treatment methods. Improving income levels could increase healthcare spending, pushing the adoption of hemophilia treatment in the forthcoming years.
**Browse our report store – GMIPulse - https://www.gminsights.com/gmipulse**
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
**Contact Us: **
Aashit Tiwari
Corporate Sales, USA
Global Market Insights Inc.
Toll Free: +1-888-689-0688
USA: +1-302-846-7766
Europe: +44-742-759-8484
APAC: +65-3129-7718
Email: mailto:sales@gminsights.com
Details
New
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
Pricing
This product is available free of charge. Free subscriptions have no end date and may be canceled any time.
Additional AWS infrastructure costs may apply. Use the AWS Pricing Calculator to estimate your infrastructure costs.
Dimensions summary
This listing uses a single pricing dimension: Product Access measured in Units, offered at no cost. You get subscriber access to the market research report through this one option. There are no tiers, instance sizes, or usage-based add-ons to choose from. The report covers the hemophilia treatment market with segmentation by disease type, product, patient, treatment regime, therapy, route of administration, end use, and region, plus forecasts through 2035. Since only one dimension applies, your access does not scale up or down by quantity or usage — you subscribe once to receive the product.
Top-of-mind questions for buyers
One Unit grants a subscriber access to the market research report. The report covers the hemophilia treatment market with segmentation by disease type, product, patient, treatment regime, therapy, route of administration, end use, and region, plus forecasts through 2035. Access is delivered in PDF, Excel, and dataset formats.
No. This listing offers a single Product Access dimension at no cost. There are no usage meters, per-seat charges, or overage thresholds. Your access does not scale up or down by quantity or activity. You subscribe once to receive the product.
The report provides estimates and forecasts in revenue terms from 2022 through 2035. It was published in December 2025, using the most recent completed year as the base. Coverage spans global, regional, and country-level markets across the listed segments.
www.gminsights.com
Helpful?
Vendor refund policy
Not applicable - product available free of charge.
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA) .
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
GMI APAC | All historical revisions | No future revisions | Not included | Not included |